Although there are no generic versions of Mounjaro, compounded tirzepatide is often suggested as an alternative
The primary target of managing MASLD is lifestyle modification, including dietary changes and increased physical activity
This is the hope
Hruby, the University of Arizona, the Arizona Board of Regents, the original technology licensee Competitive Technologies, the subsequent licensees Palatin Technologies or Clinuvel Pharmaceuticals, and Peerless Peptides.
Key findings from this phase 2 obesity trial included: Mean weight reduction of up to approximately 24.2% at the highest dose (12 mg) after 48 weeks Dose-dependent reductions in body weight across all active treatment arms Significant reductions in waist circumference, blood pressure, and lipid parameters Improvements in fasting glucose and insulin resistance markers A separate phase 2 trial in adults with type 2 diabetes (published in 2023) demonstrated meaningful HbA1c reductions alongside substantial weight loss, suggesting potential dual utility in both obesity and glycaemic management
Finally, semaglutides impact on kidney function is worth mentioning, especially since kidneys play a key role in urination
